SCHEMBL5541277

SCHEMBL5541277

[CH2]CCCCCC(=O)c1ccccc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 1/20 0.49
FEN1 P39748 1/20 0.49
CES2 O00748 1/20 0.47
CES1 P23141 1/20 0.47
ALDH1A1 P00352 3/20 0.46
MAPT P10636 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
LMNA P02545 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
DRD2 P14416 1/20 0.44
POLB P06746 1/20 0.43
HPGD P15428 2/20 0.41
CYP1A2 P05177 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HDAC1 Q13547 3/20 0.41
HDAC8 Q9BY41 2/20 0.41
HDAC3 O15379 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546417 0.98 ERCC5 (0.50) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL5544579 0.93 ERCC5 (0.51) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL5535782 0.85 ERCC5 (0.55) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL29219464 0.83 HPGD (0.55) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL7381039 0.83 ERCC5 (0.49) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL23515028 0.82 HDAC3 (0.56) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL5661990 0.82 ERCC5 (0.51) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL15979733 0.81 CES2 (0.62) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL20508903 0.81 ERCC5 (0.50) ERCC5FEN1CES2CES1ALDH1A1
SCHEMBL2113189 0.81 CYP19A1 (0.51) ALDH1A1MAPTL3MBTL1LMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ERCC5 4470/4885FEN1 3996/4885CES2 3025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.